• Norsk
  • English


Find your future partner!

At Partnership for Life Inven2 will organize a one-to-one meeting session where we invite companies, startups, investors and academia. Use the opportunity to meet for 20 minutes with other experts within pharma, biotech and medtech.


  • Expand your knowledge
  • Exchange competence
  • Extend your network
  • Identify possible areas for collaboration



We use Brella Software for the one-to-one meeting session. Find researchers, entrepreneurs or companies that match your interest and book meetings ahead of the event. For more information about Brella Software follow this link.

How to use Brella:

Download app (iOS or Android) and use join code: PFL2020 or sign in for the web version using this link.

1) Sign in/register with your LinkedIn account (recommended) or create Brella-account

2) Choose your interests and Brella will match you with other attendees

3) You are ready to schedule meetings.

For researchers at UiO /OUS and companies looking to collaborate with academia, Inven2 is here to help you find relevant collaboration partners. Please contact lise.rodsten@inven2.com

Inven2 is an innovation company owned by the University of Oslo and Oslo University Hospital responsible for commercializing research results from our owners. Our goal is to make research benefit society and to contribute to value creation.

Some of the companies interested in collaboration:


Partnering for scientific leadership

We know that innovation doesn’t happen in isolation, so we partner with others around the world, including academia, governments, industry and scientific organizations to access the best science and contribute complementary technologies, know-how and molecules.

Our main areas of interest are: Cardiovascular & Metabolic diseases; oncology; respiratory & autoimmunity; infection, vaccines & neuroscience; personalized healthcare and technology.

For further read: https://www.astrazeneca.com/Partnering.html



At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp.

Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.

For further read: https://www.biogen.com/


AbbVie er et forskningsdrevet, biofarmasøytisk selskap som jobber for å utvikle innovative og bærekraftige behandlingsløsninger for alvorlige sykdommer. Målet vårt er å gi syke mennesker bedre livskvalitet. Med vitenskap, kompetanse og engasjement ønsker vi å flytte grensene for hva som er mulig å oppnå med medisinsk behandling – med fokus på menneskene som berøres. De beste løsningene skaper vi sammen, derfor samarbeider vi med helsepersonell og -organisasjoner for å løse fremtidens helseutfordringer. Våre fokusområder er immunologi, nevrologi, onkologi og virologi. AbbVie er etablert i 170 land og har cirka 29 000 medarbeidere. I 2019 opprettet vi en organisasjon for Sverige, Norge og Danmark med til sammen 230 medarbeidere og kontorer i Stockholm, Oslo og København.

Our Search & Evaluation

AbbVie is focused on identifying and evaluating new opportunities that complement and enhance our existing internal innovation strategies.

Therapeutic Areas of Focus include Immunology, Oncology, and Neurology. For a complete list and details, please see; https://www.abbvie.com/partnerships/areas-of-interest.html

During this session, AbbVie will be represented by Director Search & Evaluation for Western Europe Sergio Capancioni. Sergio is responsible for Identify partnering opportunities that are well-aligned with the overarching business strategy of Abbvie (Oncology, Immunology, Neuroscience). Lead, guide, and carry out scientific/technical/strategic fit assessments of individual partnering opportunities, from first scans to completion of full scientific/technical due diligence.

Read more about AbbVie on www.abbvie.com or contact our medical lead in Norway, Hilde Abrahamsen Enserink,  hilde.abrahamsen@abbvie.com.



Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.

A growing and aging world population requires an adequate supply of food and improved medical care. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer. All this goes to make up our purpose:

For further read: www.bayer.no, www.bayer.com